These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27223439)

  • 1. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
    Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
    Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
    Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
    Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
    Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
    Liu SY; Gou LY; Li AN; Lou NN; Gao HF; Su J; Yang JJ; Zhang XC; Shao Y; Dong ZY; Zhou Q; Zhong WZ; Wu YL
    J Thorac Oncol; 2016 Sep; 11(9):1503-10. PubMed ID: 27257131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
    Heist RS; Shim HS; Gingipally S; Mino-Kenudson M; Le L; Gainor JF; Zheng Z; Aryee M; Xia J; Jia P; Jin H; Zhao Z; Pao W; Engelman JA; Iafrate AJ
    Oncologist; 2016 Apr; 21(4):481-6. PubMed ID: 27022036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With
    Hur JY; Ku BM; Shim JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    In Vivo; 2020; 34(3):1399-1406. PubMed ID: 32354937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
    Fischer A; Bankel L; Hiltbrunner S; Rechsteiner M; Rüschoff JH; Rushing EJ; Britschgi C; Curioni-Fontecedro A
    Target Oncol; 2022 Nov; 17(6):683-694. PubMed ID: 36136211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
    Yin L; Lu Y
    Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
    Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
    Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
    Qiu T; Li W; Zhang T; Xing P; Huang W; Wang B; Chu L; Guo L; Liu X; Li Y; Ying J; Li J
    Clin Lung Cancer; 2018 Jul; 19(4):e391-e398. PubMed ID: 29338938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of
    Yu Y; Zhang Q; Zhang J; Lu S
    J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
    Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.